Peripartum outcomes after combined myo-inositol, probiotics, and micronutrient supplementation from preconception: the NiPPeR randomized controlled trial.

assisted delivery blood loss cesarean delivery delay in second stage of labor delivery outcomes instrumental delivery labor progress operative delivery postpartum hemorrhage pregnancy

Journal

American journal of obstetrics & gynecology MFM
ISSN: 2589-9333
Titre abrégé: Am J Obstet Gynecol MFM
Pays: United States
ID NLM: 101746609

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 29 07 2022
accepted: 08 08 2022
pubmed: 16 8 2022
medline: 16 8 2022
entrez: 15 8 2022
Statut: ppublish

Résumé

Evidence that nutritional supplementation before and during pregnancy improves peripartum outcomes is sparse. In the Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health (NiPPeR) trial, we previously reported that a combined myo-inositol, probiotics, and micronutrient supplement started at preconception showed no difference in the primary outcome of gestational glycemia, but did reduce the risk of preterm delivery, preterm prelabor rupture of membranes, and major postpartum hemorrhage. This study aimed to examine the hypothesis that a reduction in major postpartum hemorrhage following a combined nutritional (myo-inositol, probiotics, and micronutrients) intervention is linked with promotion of labor progress and reduced operative delivery. This double-blind randomized controlled trial recruited 1729 women from the United Kingdom, Singapore, and New Zealand, aged 18 to 38 years, and planning conception between 2015 and 2017. The effects of the nutritional intervention compared with those of a standard micronutrient supplement (control), taken at preconception and throughout pregnancy, were examined for the secondary outcomes of peripartum events using multinomial, Poisson, and linear regression adjusting for site, ethnicity, and important covariates. Of the women who conceived and progressed beyond 24 weeks' gestation with a singleton pregnancy (n=589), 583 (99%) provided peripartum data. Between women in the intervention (n=293) and control (n=290) groups, there were no differences in rates of labor induction, oxytocin augmentation during labor, instrumental delivery, perineal trauma, and intrapartum cesarean delivery. Although duration of the first stage of labor was similar, the second-stage duration was 20% shorter in the intervention than in the control group (adjusted mean difference, -12.0 [95% confidence interval, -22.2 to -1.2] minutes; P=.029), accompanied by a reduction in operative delivery for delayed second-stage progress (adjusted risk ratio, 0.61 [0.48-0.95]; P=.022). Estimated blood loss was 10% lower in the intervention than in the control group (adjusted mean difference, -35.0 [-70.0 to -3.5] mL; P=.047), consistent with previous findings of reduced postpartum hemorrhage. Supplementation with a specific combination of myo-inositol, probiotics, and micronutrients started at preconception and continued in pregnancy reduced the duration of the second stage of labor, the risk of operative delivery for delay in the second stage, and blood loss at delivery.

Sections du résumé

BACKGROUND BACKGROUND
Evidence that nutritional supplementation before and during pregnancy improves peripartum outcomes is sparse. In the Nutritional Intervention Preconception and During Pregnancy to Maintain Healthy Glucose Metabolism and Offspring Health (NiPPeR) trial, we previously reported that a combined myo-inositol, probiotics, and micronutrient supplement started at preconception showed no difference in the primary outcome of gestational glycemia, but did reduce the risk of preterm delivery, preterm prelabor rupture of membranes, and major postpartum hemorrhage.
OBJECTIVE OBJECTIVE
This study aimed to examine the hypothesis that a reduction in major postpartum hemorrhage following a combined nutritional (myo-inositol, probiotics, and micronutrients) intervention is linked with promotion of labor progress and reduced operative delivery.
STUDY DESIGN METHODS
This double-blind randomized controlled trial recruited 1729 women from the United Kingdom, Singapore, and New Zealand, aged 18 to 38 years, and planning conception between 2015 and 2017. The effects of the nutritional intervention compared with those of a standard micronutrient supplement (control), taken at preconception and throughout pregnancy, were examined for the secondary outcomes of peripartum events using multinomial, Poisson, and linear regression adjusting for site, ethnicity, and important covariates.
RESULTS RESULTS
Of the women who conceived and progressed beyond 24 weeks' gestation with a singleton pregnancy (n=589), 583 (99%) provided peripartum data. Between women in the intervention (n=293) and control (n=290) groups, there were no differences in rates of labor induction, oxytocin augmentation during labor, instrumental delivery, perineal trauma, and intrapartum cesarean delivery. Although duration of the first stage of labor was similar, the second-stage duration was 20% shorter in the intervention than in the control group (adjusted mean difference, -12.0 [95% confidence interval, -22.2 to -1.2] minutes; P=.029), accompanied by a reduction in operative delivery for delayed second-stage progress (adjusted risk ratio, 0.61 [0.48-0.95]; P=.022). Estimated blood loss was 10% lower in the intervention than in the control group (adjusted mean difference, -35.0 [-70.0 to -3.5] mL; P=.047), consistent with previous findings of reduced postpartum hemorrhage.
CONCLUSION CONCLUSIONS
Supplementation with a specific combination of myo-inositol, probiotics, and micronutrients started at preconception and continued in pregnancy reduced the duration of the second stage of labor, the risk of operative delivery for delay in the second stage, and blood loss at delivery.

Identifiants

pubmed: 35970494
pii: S2589-9333(22)00146-X
doi: 10.1016/j.ajogmf.2022.100714
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

100714

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Shiao-Yng Chan (SY)

Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore (Drs Chan and Chong); Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore (Drs Chan, Yong, and Zhang, Mr Wong, and Dr Chong); Department of Obstetrics and Gynaecology, National University Hospital, Singapore (Dr Chan, Ms Chang, Drs Ong, Ebreo, and Chong). Electronic address: obgchan@nus.edu.sg.

Hannah E J Yong (HEJ)

Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore (Drs Chan, Yong, and Zhang, Mr Wong, and Dr Chong).

Hsin Fang Chang (HF)

Department of Obstetrics and Gynaecology, National University Hospital, Singapore (Dr Chan, Ms Chang, Drs Ong, Ebreo, and Chong).

Sheila J Barton (SJ)

Medical Research Council Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom (Dr Barton, Ms Galani, Dr El-Heis, Ms Nield, and Dr Godfrey).

Sevasti Galani (S)

Medical Research Council Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom (Dr Barton, Ms Galani, Dr El-Heis, Ms Nield, and Dr Godfrey).

Han Zhang (H)

Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore (Drs Chan, Yong, and Zhang, Mr Wong, and Dr Chong).

Jui-Tsung Wong (JT)

Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore (Drs Chan, Yong, and Zhang, Mr Wong, and Dr Chong).

Judith Ong (J)

Department of Obstetrics and Gynaecology, National University Hospital, Singapore (Dr Chan, Ms Chang, Drs Ong, Ebreo, and Chong).

Marilou Ebreo (M)

Department of Obstetrics and Gynaecology, National University Hospital, Singapore (Dr Chan, Ms Chang, Drs Ong, Ebreo, and Chong).

Sarah El-Heis (S)

Medical Research Council Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom (Dr Barton, Ms Galani, Dr El-Heis, Ms Nield, and Dr Godfrey).

Timothy Kenealy (T)

Liggins Institute, University of Auckland, Auckland, New Zealand (Drs Kenealy and Cutfield).

Heidi Nield (H)

Medical Research Council Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom (Dr Barton, Ms Galani, Dr El-Heis, Ms Nield, and Dr Godfrey).

Philip N Baker (PN)

College of Life Sciences, University of Leicester, Leicester, United Kingdom (Dr Baker).

Yap Seng Chong (YS)

Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore (Drs Chan and Chong); Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore (Drs Chan, Yong, and Zhang, Mr Wong, and Dr Chong); Department of Obstetrics and Gynaecology, National University Hospital, Singapore (Dr Chan, Ms Chang, Drs Ong, Ebreo, and Chong).

Wayne S Cutfield (WS)

Liggins Institute, University of Auckland, Auckland, New Zealand (Drs Kenealy and Cutfield); A Better Start, National Science Challenge, Auckland, New Zealand (Dr Cutfield); A Better Start, National Science Challenge, Auckland, New Zealand.

Keith M Godfrey (KM)

Medical Research Council Lifecourse Epidemiology Centre, University of Southampton, Southampton General Hospital, Southampton, United Kingdom (Dr Barton, Ms Galani, Dr El-Heis, Ms Nield, and Dr Godfrey); National Institute for Health Research Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton, National Health Service (NHS) Foundation Trust, Southampton, United Kingdom (Dr Godfrey).

Classifications MeSH